Mechanisms of Myeloid Cell Modulation of Atherosclerosis
- Authors: Filip K. Swirski1, Matthias Nahrendorf2, Peter Libby3
- Editor: Siamon Gordon4
-
VIEW AFFILIATIONS HIDE AFFILIATIONSAffiliations: 1: Center for Systems Biology, Massachusetts General Hospital, Boston, MA 02114; 2: Center for Systems Biology, Massachusetts General Hospital, Boston, MA 02114; 3: Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115; 4: Oxford University, Oxford, United Kingdom
-
Received 27 October 2015 Accepted 21 January 2016 Published 19 August 2016
- Correspondence: Peter Libby, [email protected]

-
Abstract:
Inflammation furnishes a series of pathogenic pathways that couple the risk factors for atherosclerosis with altered behavior of the intrinsic cells of the arterial wall, endothelium, and smooth muscle and promote the disease and its complications. Myeloid cells participate critically in all phases of atherosclerosis from initiation through progression, and ultimately the thrombotic consequences of this disease. Foam cells, lipid-laden macrophages, constitute the hallmark of atheromata. Much of the recent expansion in knowledge of the roles of myeloid cells in atherosclerosis revolves around the functional contributions of subsets of monocytes, precursors of macrophages, the most abundant myeloid cells in the atheroma. Proinflammatory monocytes preferentially accumulate in nascent atherosclerotic plaques. The most dramatic manifestations of atherosclerosis result from blood clot formation. Myocardial infarction, ischemic stroke, and abrupt limb ischemia all arise primarily from thrombi that complicate atherosclerotic plaques. Myeloid cells contribute pivotally to triggering thrombosis, for example, by elaborating enzymes that degrade the plaque’s protective extracellular matrix, rendering it fragile, and by producing the potent procoagulant tissue factor. While most attention has focused on mononuclear phagocytes, the participation of polymorphonuclear leukocytes may aggravate local thrombus formation. Existing therapies such as statins may exert some of their protective effects by altering the functions of myeloid cells. The pathways of innate immunity that involve myeloid cells provide a myriad of potential targets for modifying atherosclerosis and its complications, and provide a fertile field for future attempts to address the residual burden of this disease, whose global prevalence is on the rise.
-
Citation: Swirski F, Nahrendorf M, Libby P. 2016. Mechanisms of Myeloid Cell Modulation of Atherosclerosis. Microbiol Spectrum 4(4):MCHD-0026-2015. doi:10.1128/microbiolspec.MCHD-0026-2015.




Mechanisms of Myeloid Cell Modulation of Atherosclerosis, Page 1 of 2
< Previous page | Next page > /docserver/preview/fulltext/microbiolspec/4/4/MCHD-0026-2015-1.gif /docserver/preview/fulltext/microbiolspec/4/4/MCHD-0026-2015-2.gif

References

Article metrics loading...
Abstract:
Inflammation furnishes a series of pathogenic pathways that couple the risk factors for atherosclerosis with altered behavior of the intrinsic cells of the arterial wall, endothelium, and smooth muscle and promote the disease and its complications. Myeloid cells participate critically in all phases of atherosclerosis from initiation through progression, and ultimately the thrombotic consequences of this disease. Foam cells, lipid-laden macrophages, constitute the hallmark of atheromata. Much of the recent expansion in knowledge of the roles of myeloid cells in atherosclerosis revolves around the functional contributions of subsets of monocytes, precursors of macrophages, the most abundant myeloid cells in the atheroma. Proinflammatory monocytes preferentially accumulate in nascent atherosclerotic plaques. The most dramatic manifestations of atherosclerosis result from blood clot formation. Myocardial infarction, ischemic stroke, and abrupt limb ischemia all arise primarily from thrombi that complicate atherosclerotic plaques. Myeloid cells contribute pivotally to triggering thrombosis, for example, by elaborating enzymes that degrade the plaque’s protective extracellular matrix, rendering it fragile, and by producing the potent procoagulant tissue factor. While most attention has focused on mononuclear phagocytes, the participation of polymorphonuclear leukocytes may aggravate local thrombus formation. Existing therapies such as statins may exert some of their protective effects by altering the functions of myeloid cells. The pathways of innate immunity that involve myeloid cells provide a myriad of potential targets for modifying atherosclerosis and its complications, and provide a fertile field for future attempts to address the residual burden of this disease, whose global prevalence is on the rise.

Full text loading...
Figures
Roles of myeloid cells in the evolution of the atherosclerotic plaque. This figure depicts the participation of myeloid cells in the evolution of the atheroma from the inception (left) through the progression and complication of the plaque (middle to right). Dendritic cells may populate the normal arterial intima. Early in the atherogenesis, monocytes adhere to endothelial cells (left). The adherent monocytes can diapedese into the intima and mature into macrophages. These cells imbibe lipid and become foam cells, a hallmark of the atheromatous plaque. These cells populate the lipid core of the evolving atheroma (yellow central potion, middle.) These foamy macrophages can elaborate many mediators that amplify and sustain the atherogenic process. In particular, they can secrete interstitial collagenases, members of the MMP family, that can degrade the collagen fibrils that lend strength to the fibrous cap that overlies the lipid core of the established atheroma. Cleavage of collagen in the plaque’s fibrous cap allows contact of the blood coagulation components with the procoagulant tissue factor produced by the plaque macrophages. Thus, disruption of the plaque by a fracture of the fibrous cap triggers thrombosis that leads to the most dreaded clinical complications of atherosclerosis such as the acute coronary syndromes and many ischemic strokes. Macrophages can die within plaques, as shown by the cell with the pyknotic nucleus casting off apoptotic bodies that can bear tissue factor. Macrophages can also release microparticles that can provide a nidus for spotty calcification associated with plaque instability. Calcium mineral can coalesce into plates that complicate the advanced atherosclerotic plaque. As plaques mature, they can become less cellular and accumulate more extracellular matrix. In regions of plaques rich in proteoglycan and glycosaminoglycans, endothelial cells can detach, exposing blood to underlying collagen and other thrombogenic mediators that can instigate clot formation. This process, denoted superficial erosion, can lead to recruitment of polymorphonuclear leukocytes (PMNs). Dying granulocytes release DNA that can associate with the pro-oxidant enzyme myeloperoxidase, the procoagulant tissue factor, and other enzymes associated with further endothelial damage and thrombosis. These NETs can further entrap platelets, promoting propagation of thrombi. The dendritic cells in plaques can present antigen to T cells, providing a link between innate and adaptive immunity. Mast cells in the adventitia of arteries can elaborate numerous mediators including histamine, heparin, serine proteinases, and cytokines that can amplify atherogenesis and lesion complication. Thus, myeloid cells participate in all phases of atherogenesis, from lesion initiation (left) through thrombotic complications (middle and right).

Click to view
FIGURE 1
Roles of myeloid cells in the evolution of the atherosclerotic plaque. This figure depicts the participation of myeloid cells in the evolution of the atheroma from the inception (left) through the progression and complication of the plaque (middle to right). Dendritic cells may populate the normal arterial intima. Early in the atherogenesis, monocytes adhere to endothelial cells (left). The adherent monocytes can diapedese into the intima and mature into macrophages. These cells imbibe lipid and become foam cells, a hallmark of the atheromatous plaque. These cells populate the lipid core of the evolving atheroma (yellow central potion, middle.) These foamy macrophages can elaborate many mediators that amplify and sustain the atherogenic process. In particular, they can secrete interstitial collagenases, members of the MMP family, that can degrade the collagen fibrils that lend strength to the fibrous cap that overlies the lipid core of the established atheroma. Cleavage of collagen in the plaque’s fibrous cap allows contact of the blood coagulation components with the procoagulant tissue factor produced by the plaque macrophages. Thus, disruption of the plaque by a fracture of the fibrous cap triggers thrombosis that leads to the most dreaded clinical complications of atherosclerosis such as the acute coronary syndromes and many ischemic strokes. Macrophages can die within plaques, as shown by the cell with the pyknotic nucleus casting off apoptotic bodies that can bear tissue factor. Macrophages can also release microparticles that can provide a nidus for spotty calcification associated with plaque instability. Calcium mineral can coalesce into plates that complicate the advanced atherosclerotic plaque. As plaques mature, they can become less cellular and accumulate more extracellular matrix. In regions of plaques rich in proteoglycan and glycosaminoglycans, endothelial cells can detach, exposing blood to underlying collagen and other thrombogenic mediators that can instigate clot formation. This process, denoted superficial erosion, can lead to recruitment of polymorphonuclear leukocytes (PMNs). Dying granulocytes release DNA that can associate with the pro-oxidant enzyme myeloperoxidase, the procoagulant tissue factor, and other enzymes associated with further endothelial damage and thrombosis. These NETs can further entrap platelets, promoting propagation of thrombi. The dendritic cells in plaques can present antigen to T cells, providing a link between innate and adaptive immunity. Mast cells in the adventitia of arteries can elaborate numerous mediators including histamine, heparin, serine proteinases, and cytokines that can amplify atherogenesis and lesion complication. Thus, myeloid cells participate in all phases of atherogenesis, from lesion initiation (left) through thrombotic complications (middle and right).
Monocyte and macrophage diversity in relation to cardiovascular homeostasis. Blood monocytes derive from hematopoiesis in the bone marrow or from extramedullary hematopoiesis in the spleen that harbors a preformed pool of proinflammatory monocytes in mice. Monocytes enter tissues in response to chemoattractants that engage the chemokine receptors CCR2, CCR5, and CX3CR1. Hematopoietic growth factors, notably CSF-1 (M-CSF), promote the maturation of monocytes into tissue macrophages. Once recruited to and resident in tissues, macrophages can polarize toward a proinflammatory set of functions including production of cytokines such as TNF or IL-1 isoforms. IRF5 provides an example of a transcription factor that promotes the polarization of macrophages toward the proinflammatory palette of functions. The transcription factor NF-κB regulates the genes that encode a number of proinflammatory mediators elaborated by the proinflammatory subset of macrophages (pink box). Monocytes/macrophages can modulate toward a reparative and resolution-promoting set of functions under the influence of various transcription factors including nuclear receptor subfamily 4 group a member 1 (NR4a1), also known as Nur77. Mediators elaborated by the reparative subset of macrophages include IL-10; vascular endothelial growth factor (VEGF), a stimulator of angiogenesis; and transforming growth factor β (TGF-β), an anti-inflammatory and fibrogenic protein. The balance between the proinflammatory versus anti-inflammatory, reparative, and resolution functions of macrophages determines critical aspects of atherogenesis and aspects of myocardial disease related to repair of ischemic injury and the responses to hemodynamic overload conditions, features of myocardial remodeling critical in determining clinical course including the development of heart failure. ROS, reactive oxygen species (e.g., superoxide anion and hypochlorous acid); RNS, reactive nitrogen species (e.g., nitric oxide).

Click to view
FIGURE 2
Monocyte and macrophage diversity in relation to cardiovascular homeostasis. Blood monocytes derive from hematopoiesis in the bone marrow or from extramedullary hematopoiesis in the spleen that harbors a preformed pool of proinflammatory monocytes in mice. Monocytes enter tissues in response to chemoattractants that engage the chemokine receptors CCR2, CCR5, and CX3CR1. Hematopoietic growth factors, notably CSF-1 (M-CSF), promote the maturation of monocytes into tissue macrophages. Once recruited to and resident in tissues, macrophages can polarize toward a proinflammatory set of functions including production of cytokines such as TNF or IL-1 isoforms. IRF5 provides an example of a transcription factor that promotes the polarization of macrophages toward the proinflammatory palette of functions. The transcription factor NF-κB regulates the genes that encode a number of proinflammatory mediators elaborated by the proinflammatory subset of macrophages (pink box). Monocytes/macrophages can modulate toward a reparative and resolution-promoting set of functions under the influence of various transcription factors including nuclear receptor subfamily 4 group a member 1 (NR4a1), also known as Nur77. Mediators elaborated by the reparative subset of macrophages include IL-10; vascular endothelial growth factor (VEGF), a stimulator of angiogenesis; and transforming growth factor β (TGF-β), an anti-inflammatory and fibrogenic protein. The balance between the proinflammatory versus anti-inflammatory, reparative, and resolution functions of macrophages determines critical aspects of atherogenesis and aspects of myocardial disease related to repair of ischemic injury and the responses to hemodynamic overload conditions, features of myocardial remodeling critical in determining clinical course including the development of heart failure. ROS, reactive oxygen species (e.g., superoxide anion and hypochlorous acid); RNS, reactive nitrogen species (e.g., nitric oxide).
Distinctions between superficial erosion and fibrous cap rupture as causes of arterial thrombosis. Source: reference 84 , with permission.

Click to view
FIGURE 3
Distinctions between superficial erosion and fibrous cap rupture as causes of arterial thrombosis. Source: reference 84 , with permission.
A depiction of potential pathophysiologic pathways that yield superficial erosion and thrombosis on atherosclerotic plaques. The bottom of the diagram depicts a longitudinal section of an artery that harbors an extracellular matrix-rich atheroma. The darker brown indicates accumulation of the proteoglycans such as versican and biglycan and of the glycosaminoglycan hyaluronic acid. (1) Some possible triggers for endothelial damage that causes superficial erosion. Inciting stimuli could include pathogen-associated molecular patterns (PAMPs), danger-associated molecular patterns (DAMPs), or other ligands for innate immune receptors, including Toll-like receptor 2 (TLR2). These ligands bind to pattern recognition receptors on the surface of the endothelial cell. Hyaluronan, a common constituent of plaques that have undergone superficial erosion, can activate TLR2. Various apoptotic stimuli elaborated by myeloid cells in plaques, as well as oxidized lipoproteins, can unleash endothelial apoptosis. Matrix-degrading enzymes including MMPs can catabolize constituents of the basement membrane that comprises a substrate for endothelial cell adherence via integrins or other adhesion molecules. The nonfibrillar collagenases MMP-2 and MMP-9 and the activator of MMP-2, MMP-14, enzymes that localize in atheromata, may cleave the tethers of the endothelial cell to the basement membrane. (2) Some of the downstream effects of erosion. Once an endothelial cell has sloughed (as portrayed by the endothelial cell with nuclear pycnosis), the moribund endothelial cell can spew forth microparticles rich in tissue factor, a potent procoagulant. Uncovering the subendothelial matrix stimulates sticking of granulocytes and their activation and degranulation. Granulocytes elaborate reactive oxygen species (ROS) such as hypochlorous acid, HOCI, produced by myeloperoxidase (MPO), as well as superoxide anion (O2 –). This scheme postulates arrival of granulocytes secondarily, only after the initial disturbance of the endothelial monolayer. Granulocytes can also release myeloid-related protein (MRP) 8/14, a calgranulin family member implicated in inflammation and other aspects of atherothrombosis. Agonal granulocytes release DNA and citrullinated histones that contribute to NETosis, the formation of NETs. NETs can promote propagation of thrombosis and entrap further myeloid cells and platelets that amplify regional inflammation. Exposure of the subendothelial extracellular matrix macromolecules can also activate platelets, triggering their degranulation and elaboration of proinflammatory mediators including IL-6 and RANTES. In addition, activated platelets release plasminogen activator inhibitor-1 (PAI-1), which inhibits endogenous fibrinolysis, stabilizing clots. PMN, polymorphonuclear leukocyte. Source: reference 66 , with permission.

Click to view
FIGURE 4
A depiction of potential pathophysiologic pathways that yield superficial erosion and thrombosis on atherosclerotic plaques. The bottom of the diagram depicts a longitudinal section of an artery that harbors an extracellular matrix-rich atheroma. The darker brown indicates accumulation of the proteoglycans such as versican and biglycan and of the glycosaminoglycan hyaluronic acid. (1) Some possible triggers for endothelial damage that causes superficial erosion. Inciting stimuli could include pathogen-associated molecular patterns (PAMPs), danger-associated molecular patterns (DAMPs), or other ligands for innate immune receptors, including Toll-like receptor 2 (TLR2). These ligands bind to pattern recognition receptors on the surface of the endothelial cell. Hyaluronan, a common constituent of plaques that have undergone superficial erosion, can activate TLR2. Various apoptotic stimuli elaborated by myeloid cells in plaques, as well as oxidized lipoproteins, can unleash endothelial apoptosis. Matrix-degrading enzymes including MMPs can catabolize constituents of the basement membrane that comprises a substrate for endothelial cell adherence via integrins or other adhesion molecules. The nonfibrillar collagenases MMP-2 and MMP-9 and the activator of MMP-2, MMP-14, enzymes that localize in atheromata, may cleave the tethers of the endothelial cell to the basement membrane. (2) Some of the downstream effects of erosion. Once an endothelial cell has sloughed (as portrayed by the endothelial cell with nuclear pycnosis), the moribund endothelial cell can spew forth microparticles rich in tissue factor, a potent procoagulant. Uncovering the subendothelial matrix stimulates sticking of granulocytes and their activation and degranulation. Granulocytes elaborate reactive oxygen species (ROS) such as hypochlorous acid, HOCI, produced by myeloperoxidase (MPO), as well as superoxide anion (O2 –). This scheme postulates arrival of granulocytes secondarily, only after the initial disturbance of the endothelial monolayer. Granulocytes can also release myeloid-related protein (MRP) 8/14, a calgranulin family member implicated in inflammation and other aspects of atherothrombosis. Agonal granulocytes release DNA and citrullinated histones that contribute to NETosis, the formation of NETs. NETs can promote propagation of thrombosis and entrap further myeloid cells and platelets that amplify regional inflammation. Exposure of the subendothelial extracellular matrix macromolecules can also activate platelets, triggering their degranulation and elaboration of proinflammatory mediators including IL-6 and RANTES. In addition, activated platelets release plasminogen activator inhibitor-1 (PAI-1), which inhibits endogenous fibrinolysis, stabilizing clots. PMN, polymorphonuclear leukocyte. Source: reference 66 , with permission.
Supplemental Material
No supplementary material available for this content.